In a non-small cell lung cancer (NSCLC) xenograft model with EGFR overexpression, those immunoliposomes showed a strongly enhanced ability for drug delivery and tumor growth inhibition. This evidence concerns the gene EGFR and non-small cell lung carcinoma.